Antibody-drug conjugate (ADC)technology is not new. The first ADC, Pfizer Inc.’s Mylotarg, reached the market two decades ago. The field has undergone slow but transformative enhancements.
ADCs Coming Of Age: Deals, Targets And Catalysts
The antibody-drug conjugate field is beginning to reach its full potential and big pharma’s attention has been caught.
